News – Page 1119 – Endpoints News

Facing a payer backlash over sticker shock, Biogen fields positive data on Spinraza for children 2-12

9 years ago

EASL Roundup: Bristol-Myers and NGM post a positive look at PhII NASH data; Genfit details PhIII delay

9 years ago

Politics, pricing controversy, tax reform and steep valuations conspire to confuse Sanofi’s M&A strategy

9 years ago

Scoop: Turing CEO and Shkreli ally Ron Tilles is out as CEO, R&D chief Salinas takes the helm and board vote looms

9 years ago

J&J faces its second rival Remicade knockoff as FDA gives Merck a shot at a $7B franchise

9 years ago

Sunil Agarwal in as head of R&D at Juno's upcoming Bay Area campus; Argos' CMO Lee Allen heads to Dova

9 years ago

Don't let a slump in biopharma deals get you down — yet; The controversy on drug prices is taking a toll

9 years ago

Celgene grabs more space in Cambridge; Karolinska Dev gets new CEO

9 years ago

It’s official: Controversial Marathon Pharmaceuticals bows out at PhRMA in wake of price gouging controversy

9 years ago

Gilead offers a glimpse at hard data to back up its $600M investment in Nimbus’ NASH drug

9 years ago

XBiotech shares crater as CHMP shudders at its application to sell Xilonix

9 years ago

Black box warning? No worries, Valeant bills Siliq as the ‘low-cost’ psoriasis alternative to rivals from ...

9 years ago

A second wave of checkpoint inhibitors is swelling fast, with speedy BeiGene leaping into a pivotal trial

9 years ago

Vernalis shares slide after FDA turn thumbs down on their latest XR cold med

9 years ago

David Meeker adds another biotech board spot to the post-Genzyme resume; J&J’s DePuy acquires 3D printing tech for ...

9 years ago

AbbVie, Enanta post stellar hep C PhIII data, but no one is cheering

9 years ago

With his day(s) in court looming, Martin Shkreli and his former lawyer win separate fraud trials

9 years ago

The list of the top 10 most expensive drugs on the planet will soon have a new opening

9 years ago

AbbVie grapples with another setback as 2 PhIII trials for its PARP veliparib flop

9 years ago

Is Tesaro playing a pricing game with Zejula? Not at all, says the CEO. And here's why

9 years ago

TherapeuticsMD flags “deficiencies” in NDA; CRUK, NCI collaborate on RAS inhibitor research

9 years ago

Time for biotechies to stand up and be counted on Kendall Square

9 years ago

That turnaround on new FDA drug approvals? We’re right on schedule

9 years ago

Ultragenyx, Kyowa Hakko Kirin plan a date with the FDA after positive PhIII for X-linked hypophosphatemia

9 years ago

First page Previous page 1116 1117 111811191120 1121 1122 Next page Last page